NK- and T-cell lymphoma - historical

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main NKTCL page for current regimens.

Last updated on 2024-07-23:
1 regimens on this page
1 variants on this page


Relapsed or refractory

Pembrolizumab monotherapy

Regimen

Study Dates of enrollment Evidence
Kwong et al. 2017 Not reported Case series

Note: prospective trials are underway.

Immunotherapy

21-day cycles

References

  1. Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 Apr 27;129(17):2437-2442. Epub 2017 Feb 10. link to original article PubMed